ZOLL Medical has completed its previously announced acquisition of medical device and digital health company Itamar Medical.
The acquisition closed nearly three months after ZOLL signed a definitive agreement to acquire Itamar Medical for nearly $538m.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
As agreed, Itamar Medical will now operate as a business division within ZOLL. The former CEO of Itamar Medical, Gilad Glick, will lead the business.
The acquired firm’s main operations in Caesarea, Israel, are also expected to continue with no material impact.
Itamar Medical focuses on developing non-invasive medical devices and solutions to help diagnose respiratory sleep disorders. The company’s main product, the WatchPAT Home Sleep Apnea Device, is available in the US, Europe and Japan.
The acquisition will enable ZOLL to enhance its offerings for undiagnosed and untreated cardiac patients.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataZOLL CEO Jon Rennert said: “We are pleased to announce the closing of the acquisition of Itamar and welcome its employees to the ZOLL family.
“Together, ZOLL and Itamar Medical will help more patients receive diagnosis and treatment for sleep-disordered breathing and help strengthen the collaboration between the worlds of cardiology and sleep medicine.”
An Asahi Kasei subsidiary, ZOLL delivers medical devices and software solutions for emergency care as well as to boost clinical and operational efficiencies.
Last year, ZOLL secured US Food and Drug Administration (FDA) approval for its TherOx System.
The TherOx System is designed to provide SuperSaturated Oxygen (SSO₂) Therapy and reduce heart muscle damage in ‘widowmaker’ heart attack patients.
